The Free State: Not So Free For Patients
Christine Gordon and others said the bill would only add fees and regulatory hurdles to cannabidiol, or CBD oil — a substance that already can be accessed legally at the federal level.
“I have CBD sitting in my kitchen,” she said. “I have CBD sitting with me right here today.”
Gordon illustrated the point by producing a small bottle of CBD oil and giving a dose to her 4-year-old daughter, Autumn, who suffers from persistent seizures.http://kcur.org/post/advocates-rally-topeka-against-watered-down-medical-marijuana-bill#stream/0
House Bill 2691, the Kansas Safe Access Act, is pending in the legislature to provide for the legal use of cannabis for medical conditions. The measure would register compassion centers, authorize the issuance of identification cards, and establish a compassion board. The program would be overseen by the Department of Health and Environment. House Bill 2691 is pending before the House Committee on Health and Human Services.
National Multiple Sclerosis Society "The Society supports the rights of people with MS to work with their MS health care providers to access marijuana for medical purposes in accordance with legal regulations in those states where such use has been approved."
The use of cannabis was associated with beneficial effects on some FM symptoms. Further studies on the usefulness of cannabinoids in FM patients as well as cannabinoid system involvement in the pathophysiology of this condition are warranted.
BREAST CANCER: Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.
The data presented in this report suggest for the first time that as an active component in the cannabis plant, CBDA offers potential therapeutic modality in the abrogation of cancer cell migration, including aggressive breast cancers.
Our data support the further testing of cannabidiol and cannabidiol-rich extracts for the potential treatment of cancer.
Cannabidiol (CBD) significantly inhibited cell viability. Other compounds became effective in cells deprived of serum for 24 h. Several BDS were more potent than the pure compounds in the presence of serum. CBD-BDS (i.p.) potentiated the effects of bicalutamide and docetaxel against LNCaP and DU-145 xenograft tumours and, given alone, reduced LNCaP xenograft size. CBD (1-10 µM) induced apoptosis and induced markers of intrinsic apoptotic pathways (PUMA and CHOP expression and intracellular Ca(2+)). In LNCaP cells, the pro-apoptotic effect of CBD was only partly due to TRPM8 antagonism and was accompanied by down-regulation of AR, p53 activation and elevation of reactive oxygen species. LNCaP cells differentiated to androgen-insensitive neuroendocrine-like cells were more sensitive to CBD-induced apoptosis.CONCLUSIONS AND IMPLICATIONS:
These data support the clinical testing of CBD against prostate carcinoma.
The Epilepsy Foundation supports the rights of patients and families living with seizures and epilepsy to access physician directed care, including medical marijuana.
The Epilepsy Foundation calls for an end to Drug Enforcement Administration (DEA) restrictions that limit clinical trails and research into medical marijuana for epilepsy.
The Epilepsy Foundation believes that an end to seizures should not be determined by one’s zip code.
Chronic non-cancer pain conditions included neuropathic pain, fibromyalgia, rheumatoid arthritis, and mixed chronic pain. Overall the quality of trials was excellent. Fifteen of the eighteen trials that met the inclusion criteria demonstrated a significant analgesic effect of cannabinoid as compared with placebo and several reported significant improvements in sleep. There were no serious adverse effects. Adverse effects most commonly reported were generally well tolerated, mild to moderate in severity and led to withdrawal from the studies in only a few cases. Overall there is evidence that cannabinoids are safe and modestly effective in neuropathic pain with preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis. The context of the need for additional treatments for chronic pain is reviewed. Further large studies of longer duration examining specific cannabinoids in homogeneous
CHRONIC PAIN: These results suggest that Cannabis is an extremely safe and effective medication for many chronic pain patients. Cannabis appears to alleviate pain, insomnia, and may be helpful in relieving anxiety.Cannabis has shown extreme promise in the treatment of numerous medical problems and deserves to be released from the current Schedule I federal prohibition against research and prescription.
In The Netherlands, pharmaceutical-grade cultivated cannabis is distributed for medicinal purposes as commissioned by the Ministry of Health. One hundred two patients were included; their average age was 53 years and 76% used it for more than a year preceding this study. Chronic pain (53%; n = 54) was the most common medical indication for using cannabis followed by multiple sclerosis (23%; n = 23), and 86% (n = 88) of patients (almost) always experienced therapeutic satisfaction when using pharmaceutical cannabis.
CBD BDS attenuates colon carcinogenesis and inhibits colorectal cancer cell proliferation via CB1 and CB2 receptor activation. The results may have some clinical relevance for the use of Cannabis-based medicines in cancer patients.
Greater than 75% reduction in CAPS symptom scores were reported when patients were using cannabis compared to when they were not.CONCLUSIONS:
Cannabis is associated with reductions in PTSD symptoms in some patients, and prospective, placebo-controlled study is needed to determine efficacy of cannabis and its constituents in treating PTSD.
PEDIATRIC EPILEPSY: Nineteen responses met the following inclusion criteria for the study: a diagnosis of epilepsy and current use of cannabidiol-enriched cannabis. Thirteen children had Dravet syndrome, four had Doose syndrome, and one each had Lennox-Gastaut syndrome and idiopathic epilepsy. The average number of antiepileptic drugs (AEDs) tried before using cannabidiol-enriched cannabiswas 12. Sixteen (84%) of the 19 parents reported a reduction in their child's seizure frequency while taking cannabidiol-enriched cannabis. Of these, two (11%) reported complete seizure freedom, eight (42%) reported a greater than 80% reduction in seizure frequency, and six (32%) reported a 25-60% seizure reduction. Other beneficial effects included increased alertness, better mood, and improved sleep. Side effects included drowsiness and fatigue. Our survey shows that parents are using cannabidiol-enriched cannabis as a treatment for their children with treatment-resistant epilepsy.
Of the 30 patients 21 improved significantly after treatment with cannabis. The average Harvey Bradshaw index improved from 14 +/- 6.7 to 7 +/- 4.7 (P < 0.001). The need for other medication was significantly reduced. Fifteen of the patients had 19 surgeries during an average period of 9 years before cannabis use, but only 2 required surgery during an average period of 3 years of cannabis use.CONCLUSIONS:
This is the first report of cannabis use in Crohn's disease in humans. The results indicate that cannabis may have a positive effect on disease activity, as reflected by reduction in disease activity index and in the need for other drugs and surgery. Prospective placebo-controlled studies are warranted to fully evaluate the efficacy and side effects of cannabis in CD.http://www.ncbi.nlm.nih.gov/pubmed/21910367
According the 2015 Kansas Speaks Poll,
68% of Kansans Support Patient's Rights to Medical Cannabis
There has been an aggressive refusal to give cannabis legislation a vote of the ENTIRE legislature. This refusal circumvents the voice of the people of Kansas and undermines the very principles of democracy in Kansas. ALL Kansans should be heard and the will of the people should guide every legislator, and every law.
Please contact the committees below and let them know that YOU support the rights of Kansas patients to medical cannabis and you want your voice to matter. Then please, contact your district representative and let them know that you do not believe these committees should be blocking your voice from being heard.
Contact your representatives and tell them to support The Kansas Safe Access Act by clicking here:
THANK YOU!! This REALLY does help us in this battle.
Tell Them to Support HB2011
Let them know that SB9 should got to the full senate for debate and the vote of EVERY senator.
WE NEED YOU!
Will you stand with us as we fight over this next year to bring compassionate relief to those Kansans who continue to suffer and die needlessly? What if it was your child or loved one? Please consider how precious these patients are to their families, friends and communities, and then reflect on the fact that unless we stand together, they have no hope in Kansas.
There is much work to be done over the next months; From emails and phone calls to speaking to the public and holding a sign at a rally, `There is something for everyone to do. Perhaps you do not have much time to donate but you can purchase some printing, t-shirts, or sign materials. That is equally as needed and as equally, gratefully, appreciated.
All of our contact information is on the CONTACT tab, located at very top. THANK YOU!
It is a crime to possess any amount cannabis (including small amounts for personal use) in Kansas. (Kan. Stat. Ann. § 21-5706(b)(3).) Violations are a class A misdemeanor, punishable with a fine of up to $2,500, up to one year in jail, or both. Second and subsequent convictions are level 4 felonies, punishable with up to 26 months in prison, and possible fines. (Kan. Stat. Ann. § 21-5706(c)(2).) Cultivating four or fewer cannabis plants is a class A nonperson misdemeanor. Penalties include a fine of up to $2,500, up to one year in jail, or both.
Cultivating or selling cannabis. A violation is a level 3 felony, punishable with up to 36 months in prison, and possible fines.
Second convictions. A violation is a level 2 felony, punishable with up to 68 months in prison, and possible fines.
Third and subsequent convictions. A violation is a level 1 felony, punishable with up to 179 months in prison, and possible fines.
Charges against Garden City mother enflame cannabis community